Influence of Angiotensin Converting Enzyme I/D Polymorphism on Hemodynamic and Antioxidant Response to Long-Term Intradialytic Resistance Training in Patients With Chronic Kidney Disease: A Randomized Controlled Trial
-
Hugo de luca Corrêa ; Lysleine Alves Deus ; Rodrigo V. Neves ; Andrea Lucena Reis [1] ; Giovana S. de Freitas [1] ; Thais B. Araujo [1] ; Jessica M. da Silva Barbosa [1] ; Jonato Prestes ; Herbert Gustavo Simões ; Carlos Eduardo Neves Amorim [2] ; Marcos Antonio Pereira dos Santos ; Anderson S. Haro ; Gislane F. de Melo ; Andre B. Gadelha [1] ; Luiz Sinesio S. Neto [3] ; Thiago Santos Rosa
-
[1] Universidade Católica de Brasília
Universidade Católica de Brasília
Brasil
-
[2] Universidade Federal do Maranhão
Universidade Federal do Maranhão
Brasil
-
[3] Faculty of Medicine, Federal University of Tocantins, Tocantins, Brazil
-
- Localización: Journal of strength and conditioning research: the research journal of the NSCA, ISSN 1064-8011, Vol. 35, Nº. 10, 2021, págs. 2902-2909
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The aim of the study was to verify the influence of Angiotensin-converting enzyme (ACE) I/D genotype on blood pressure, muscle mass, and redox balance response to long-term resistance training (RT) in end-stage renal disease patients. Three hundred and twenty subjects were randomized into 4 groups: II + ID control (II + ID CTL, n = 80), II + ID RT (II + ID RT, n = 79), DD control (DD CTL n = 83), and DD RT (DD RT, n = 78). The RT lasted 24 weeks with a frequency of 3 times per week, on alternative days. Each section consisted of 3 sets of 8-12 repetitions in 11 exercises, with training loads at 6 point (somewhat hard) to 8 point (hard) based on OMNI-RES scale and was prescribed during dialysis (intradialytic). Statistical significance was accepted with p < 0.05. The most relevant benefits in blood pressure were found for DD homozygotes (p < 0.0001), whereas allele I carriers displayed a higher increase in muscle mass (p < 0.0001). Hemodialysis clinics that already use RT for their patients could include the genotyping of ACE to identify the predisposal of the patients to respond to RT and to counteract kidney disease-related comorbidities.
